NDA 016093 · Bausch
Edecrin
Ethacrynate Sodium · Injection
Last checked: Nov 20, 2026Latest source record: Jul 20, 2005 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1967
Jan 10, 1967
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
1 Phase 3, 1 recruiting
FAERS reports
553
400 serious, 66 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 10, 1967 Original approval · Type 2 - New Active Ingredient
1 products under this application
- EDECRIN · ETHACRYNATE SODIUM EQ 50MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ethacrynate" as an intervention, any sponsor and status, largest first.
- Furosemide Versus Ethacrynic Acid in Children With Congenital Heart DiseasePivotal-lookingCompleted
Bambino Gesù Hospital and Research InstituteAcademic, hospital or other
NCT01628731 · 74 participants · Start Oct 2012 · Primary completion Jul 2013
Drug: furosemide; ethacrynic acid · For: Fluid Overload
Sites: Rome, Italy
- Phase 0 Study to Define the Effect of Low Dose Ethacrynic Acid on Total Glutathione (GSH) Levels and Glutathione S-transferase (GST) ActivityNot yet recruiting
University of Vermont Medical CenterAcademic, hospital or other
NCT07943000 · 40 participants (planned) · Start Jan 2029 · Primary completion Jan 2029
Drug: ethacrynic acid · For: Healthy Volunteers; Redox Biology
Eugene Lee, MDAcademic, hospital or other
NCT02852564 · 12 participants · Start Aug 2016 · Primary completion Jul 2017
Drug: Ethacrynic Acid · For: Bladder Cancer
Sites: Kansas City, Kansas
Molly WalshAcademic, hospital or other
NCT02051946 · 9 participants · Start May 2014 · Primary completion Oct 2015
Drug: ethacrynic acid injection; balanced salt solution · For: Glaucoma
Sites: Durham, North Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug reaction with eosinophilia and systemic symptoms59
- off label use52
- nausea48
- dyspnoea43
- drug ineffective35
- acute kidney injury33
- diarrhoea33
- drug hypersensitivity33
- fatigue32
- vomiting32
- asthenia26
- death26
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 4 |
| 2006 | 9 |
| 2007 | 7 |
| 2008 | 9 |
| 2009 | 7 |
| 2010 | 12 |
| 2011 | 18 |
| 2012 | 31 |
| 2013 | 18 |
| 2014 | 15 |
| 2015 | 23 |
| 2016 | 27 |
| 2017 | 39 |
| 2018 | 30 |
| 2019 | 40 |
| 2020 | 28 |
| 2021 | 53 |
| 2022 | 43 |
| 2023 | 46 |
| 2024 | 25 |
| 2025 | 27 |
| 2026 | 33 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Edecrin (Ethacrynic Acid)
2024 spending
$587K
Beneficiaries
53
250 claims
Per beneficiary
$11,082
$23.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $920,791 |
| 2021 | $765,609 |
| 2022 | $675,566 |
| 2023 | $517,004 |
| 2024 | $587,364 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A comparison of the diuretic effects of prostaglandin A1, sodium ethacrynate, and placebo.
Montgomery RG, Patel NC, Lee JG · Prostaglandins 1973 · Clinical Trial, Comparative Study
- A comparison of the diuretic effects of prostaglandin A1, sodium ethacrynate, and placebo.
Montgomery RG, Patel NC, Lee JG · Int J Clin Pharmacol Biopharm 1975 · Clinical Trial, Comparative Study
- Evidences for proximal tubular site of action of intravenous ethacrynic acid (Lyovac-Edecrin) obtained during antiotensin infusion in diabetes insipidus.
Radó JP, Borbély L · Endokrinologie 1970 · Clinical Trial
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.